Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Bioverativ
|
| gptkbp:acquisitionYear |
2017
|
| gptkbp:focusesOn |
rare diseases
complement system disorders |
| gptkbp:foundedIn |
2013
|
| gptkbp:founder |
gptkb:Arthur_T._Sands
Bill Rote David S. Urdal Nancy Stagliano Vikram Sheel Kumar |
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
True North Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableContributor |
treatment for cold agglutinin disease
|
| gptkbp:notableProduct |
monoclonal antibodies
complement pathway inhibitors |
| gptkbp:parentCompany |
gptkb:Bioverativ
|
| gptkbp:website |
http://www.truenorthrx.com
|
| gptkbp:bfsParent |
gptkb:Beth_Seidenberg
|
| gptkbp:bfsLayer |
7
|